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INTRODUCTION
============

*Staphylococcus aureus* is a human pathogen encapsulated bacterium with anti-phagocytic activity (26,15,30) which can invade and survive within a wide variety of mammalian cells (2,14) and causes intramammary infections in animals (27,34). The detection of a major *S. aureus* clone A (63%), infecting dairy herds, has demonstrated its geographical spread among farms in Rio de Janeiro State, Brazil, affecting five different animal species and it has been suggested that all but one of the clones was animal specific (1,34). *S. aureus* causes food poisoning epidemics in humans (5,24) by secreting staphylococcal enterotoxins (SEs). However, their role in intoxications has yet to be clarified, and descriptions of the bacterial pathogenicity continues to grow as more proteins with the same or similar properties are isolated or characterized (20,16,18,25,31). SEs are known to function as potent super-antigens that stimulate non-specific clonal T-cell proliferation, followed by a state of hyporesponsiveness to subsequent antigen stimulation and, thus, hinder the development of protective immunity, while promoting the persistence of bacteria in the host (11). SEs may also aggravate bovine intramammary infections throughout local cytokine release (40). SEs are produced by *S. aureus* after *agr* activation quorum-sensing system (QS), which consists of a sophisticated system to ensure that some bacteria functions only take place when a specific population density has been reached (3). This *agr* commanded system, however, is negatively influenced by the octapeptide RNAIII Inhibiting Peptide (RIP) *in vivo* by interfering in staphylococcal infections (4) and *in vitro* by polyclonal affinity purified antibodies anti-recTRAP, resulting in staphylococcal enterotoxins inhibition in liquid culture (35). Several plant extracts containing phenolics and alkaloid compounds may interfere with bacterial (QS) and biofilm formation (13,29).

As a group, the coagulase-negative staphylococci are among the most frequently-isolated bacteria in clinical microbiology and are becoming increasingly important, especially as causes of hospital-acquired infections, including *S. epidermidis* (37), considered a normal inhabitant of human skin and mucous membranes, but they also infect animals (32,38).

Several plant-derived compounds possess medicinal properties with activity against important medical microorganisms (17,29). A new indole alkaloid isolated from root bark was described in *Rauvolfia grandiflora,* however, its biological activity has not as yet been tested (7,8). Previous studies have shown that plant extracts can inhibit enterotoxin production by *Staphylococcus aureus* strains (22,6). A natural product found in the bark of witch hazel, hamamelitannin, had no effect on staphylococcal growth *in vitro*, but inhibited the (QS) regulator RNAIII and, in a rat graft model, prevented device-associated infections *in vivo*, including infections caused by MRSA and MRSE strains (19). The present study describes the biological activity of methanol extract from *Rauvolfia grandiflora* against staphylococci strains, and discusses the interference of enterotoxin production by *S. aureus*, cell growth inhibition and antibiotic interactions with the bacteria.

MATERIAL AND METHODS
====================

Test organisms and plant extract
--------------------------------

Root bark of *R. grandiflora* was collected in São Francisco do Itabapoana City, Rio de Janeiro State, Brazil. A voucher specimen was deposited in the herbarium of the Agricultural University of wageningem, Netherlands. Root bark samples were dried, powdered, and extracted using methanol and after solvent evaporation, all samples were dissolved in DMSO (Sigma, USA) at a concentration of 100000 μg.mL^-1^. The assays were performed using the extracts at a final concentration of 1.2 μg.mL^-1^ at RT.

Reference bacterial strains: *S. aureus* Wood 46 (ATCC10832) a capsule-negative strain, *S. aureus* Smith Diffuse (SD) (ATCC 13709) a capsule-producer strain, *S. aureus* ATCC 25923 strain, and *S. epidermidis* ATCC 12228 a non-biofilm-forming strain. Bovine *S. aureus* LSA88 (34) is a SEC/SED producing strain previously studied (35,36) and used in the development of the recombinant *sec* gene (33). All strains were re-activated in Brain Heart Infusion broth.

Fractionation of RGE
--------------------

The methodology used to obtain RGE followed a previously alkaloid extraction from *R. grandiflora* with minor modifications (8). Dried and powdered root bark (1.67 kg) from *R. grandiflora* was extracted with methanol at room temperature, resulting in 36.0g of residue, after solvent evaporation. About 95% of this residue was chromatographed on a silica gel column eluted with a methanol gradient in dichloromethane, and 10 fractions collected. Nine of these samples were re-fractionated but the concentrations were insufficient to carry out the tests. The isolated alkaloid compound isoreserpiline, obtained from dichloromethane fraction, was tested against all strains.

Experimental procedures
-----------------------

**Growth Inhibition:** An aliquot of 0.1 mL from *Rauvolfia grandiflora* root bark methanol extraction (RGE) was added to 1.8 mL of BHI and 0.1 mL of bacteria inoculum (OD~550nm~ 0.5 McFarland), determined using a photometer (Densimat, bioMérieux, France). The density readings of treatments and controls were recorded every sixty minutes. Controls employed medium and inoculums with DMSO added as a dispersing solvent. After 12 h incubation period at 37°C, 0.1 mL aliquots of cultures were streaked on BHA agar (Acumedia, USA) and incubated on 37°C.

Antibiotic activities after extract treatments
----------------------------------------------

Antibiograms were performed following exposure of strains to RGE. Pure colonies of each strain were sub-cultured on blood agar plates for antimicrobial standard disk diffusion tests, performed in agar Muller Hinton, according to the guidelines of the National Committee for Clinical Laboratory Standards (21), and the halo formed around each disk was recorded. The disks contained the following drugs: penicillin G (PEN, 10U), oxacillin (OXA, 1 μg), amoxicillin (AMO, 10 μg), ampicilin (AMP, 10 μg), cephalothin (CFL, 30 μg), cefoxitin (CFO, 30 μg), trimethoprim-sulfamethoxazole (SUT, 25 μg), clindamycin (CLI, 2 μg), erythromycin (ERI, 15 μg), gentamicin (GEN, 10 μg), tetracycline (TET 30 μg), and vancomicin (VAN, 30 μg) (Laborclin, PR, Brazil).

Growth and Enterotoxin inhibition assays
----------------------------------------

In order to evaluate the inhibition of SEC and SED secretion by LSA 88 bovine strain after treatment with RGE, ELISA assays were performed as previously described (35). After ON reactivation at 37°C, cells were harvested by centrifugation at 12 000 x *g* and washed twice in PBS. Cells were then diluted in fresh TECRA® Staphylococcal growth medium (Bioenterprises Pty. Ltd., Australia) to a density of 10^8^ cells mL^-1^ at OD~550nm~ 0.5. Tubes with cells plus DMSO were used as negative controls. Kit-positive and -negative controls were used. A proportional cell growth assay was conducted over a 2h duration, and growth of cells was interrupted by adding a stop solution. A second experiment was conducted, where *S. aureus* cell growth was monitored using a controlled incubation at 37°C for 3h for controls and 4h for treatments in order to standardize the values for cell growth and subsequent comparison of enterotoxin production. After centrifugation, supernatants were harvested and tested for SEs using the TECRA® Visual Immunoassay VIA^?^ kit (Bioenterprises Pty. Ltd., Australia), according to the manufacturer's instructions. This assay allows for the specific and sensitive detection of enterotoxins A to E (lower limit 1.0 ng.mL^-1^). Color development readings (OD~405nm~) (Biorad, USA) were realized during two intervals at the end of the assay. All the experiments described were performed in triplicate.

RESULTS
=======

Following purification of RGE, the only alkaloid compound obtained, isoreserpiline, when tested alone against the bacterial strains selected here, showed no antimicrobial activity. The structure of isoreserpiline is shown in [Figure 1](#fig1){ref-type="fig"}. The other 9 fractions resulted in very low concentrations of the alkaloids darcyribeirine and β-yohimbine obtained from methanol extract and were not tested. ELISA results, as expected, showed that RGE-treated *S. aureus* LSA88 (bovine strain) cells were inhibited and directly accompanied by a proportional decreased enterotoxin production ([Figure 2](#fig2){ref-type="fig"}), *i.e.* the lower the cell density, the lower the amount of enterotoxin detected. RGE also caused growth inhibition of all other strains when cultured on BHA agar (Tukey, p\<0.05%). Controls exhibited CFU counts above 300 colonies/mL, while RGE-treated cells presented CFU counts that were less than 300 and above 30 CFU.

ELISA experiments to determine enterotoxin production after RGE treatment revealed 20% inhibition in SE production, compared to controls, even with similar cell populations ([Figure 3](#fig3){ref-type="fig"}).

![Structure of isoreserpiline obtained from dichloromethane fraction.](bjm-41-612-g001){#fig1}

![Density of *Staphylococcus aureus* (bovine strain) cells. Color development intervals (25 and 30 minutes readings). Production of enterotoxins by LSA 88 *Staphylococcus aureus* (bovine strain) was directly dependent/proportional on cell population. RG (treatment with *Rauvolfia grandiflora* extract); PC = positive control; NC= negative control.](bjm-41-612-g002){#fig2}

![Color development intervals (10 and 20 minutes readings). Inhibition of enterotoxins produced by LSA 88 *Staphylococcus aureus* (bovine strain) cultured in liquid medium in the presence of *R. grandiflora* methanol extract, in proportional cell density (OD~550nm~) of both, treatment (Trt Ext incubated for 4h) and control (Cont DMSO incubated for 3h). PC and NC indicate positive and negative controls, respectively.](bjm-41-612-g003){#fig3}

The results of antibiograms of RGE treated cells are shown in [Tables 1A](#tbl1A){ref-type="table"}-[2B](#tbl2B){ref-type="table"}.

Individually, after antibiotic exposure of bacteria, comparing RGE treated cells and controls, the results show larger inhibition zones than those of the respective controls for most strains (p\<0.05). In contrast, *S. aureus* 25923 and Wood 46 strains, did not present larger inhibition zones after exposure to oxacillin ([Table 1A](#tbl1A){ref-type="table"}) and ampicillin ([Table 1B](#tbl1B){ref-type="table"}), respectively, suggesting no effect of the treatment. For SD strain, treatment did not affect the activity of drugs, except for amoxicillin, oxacillin, and trimethoprim-sulfamethoxazole, where RGE augmented the inhibition zones. Comparing results between drugs, cephalosporin (CFL and CFO) demonstrated greater activity than the other drugs against most of the strains tested. [Tables 2A](#tbl2A){ref-type="table"} and [2B](#tbl2B){ref-type="table"} show that the SD strain remained less sensitive to drugs, except for OXA and SUT. All other strains were responsive to RGE treatment and exhibited higher sensitivity towards the drugs tested, as confirmed by the augmentation of the inhibition zone (p\<0.05).

###### 

Antibiogram (measured in mm) of staphylococcal strains, treated with *Rauvolfia grandiflora* extract, and submitted to six drugs. Evaluated by agar diffusion method using Gram-positive A kit.

  **Strains**                                                                                      
  ------------- -------- -------- -------- -------- --------- -------- -------- -------- --------- --------
  PEN           24.0Ad   15.0Bc   23.7Ac   15.7Bd   36.3Aa    21.3Bb   16.7Ad   14.7Bd   24.3Ae    23.3Ad
  CFL           40.0Aa   32.3Ba   32.3Aa   32.0Aa   33.Ab     26.3Ba   34.0Aa   29.7Ba   38.0Aa    37.0Aa
  CLI           40.0Aa   33.0Ba   27.0Ab   20.7Bb   28.3Ad    19.7Bc   31.7Ab   27.3Bb   25.3Ade   25.3Ac
  AMO           28.3Ac   15.0Bc   24.3Ac   14.7Bd   31.3Abc   22.3Bb   17.0Ad   14.7Bd   36.7Ab    34.3Bb
  TET           19.3Ae   11.3Bd   18.0Ad   12.3Be   29.7Acd   25.7Ba   16.3Ad   13.7Bd   26.3Ad    25.7Ac
  OXA           36.3Ab   26.3Bb   23.7Ac   18.3Bc   25.0Ae    21.7Bb   21.0Bc   25.3Ac   28.0Ac    26.0Bc

GrA- Kit used for antibiogram to analyze six anti-Gram-positive A drugs; Means followed by the same small letter in the column (drug) and capital letter in the line (extract treatment), do not differ among themselves. Tukey test, 5% probability.

###### 

Antibiogram (measured in mm) of staphylococcal strains, treated by *Rauvolfia grandiflora* extract, and submitted to six drugs. Evaluated by agar diffusion method using Gram-positive B kit.

  **Strains**                                                                                        
  ------------- --------- -------- --------- -------- --------- -------- -------- --------- -------- --------
  VAN           27.7Ad    21.3Bb   20.0Ad    14.7Bd   20.7Ad    14.7Bc   18.7Ad   14.7Bd    16.7Ae   16.0Ae
  AMP           23.7Ae    13.7Bc   31.7Aa    23.7Bb   37.0Ba    40.0Aa   15.7Ae   14.3Ad    39.3Aa   35.7Aa
  ERI           31.3Ac    23.7Bb   21.7Acd   13.3Bd   25.7Ac    20.3Bb   22.0Ac   17.7Bc    17.7Ae   16.7Ae
  SUT           34.3Ab    22.7Bb   28.3Ab    17.7Bc   32.0Ab    20.7Bb   28.3Ab   23.0Bb    25.7Ac   24.0Bc
  GEN           33.0Abc   24.0Bb   23.3Ac    17.0Bc   25.0Ac    18.7Bb   21.3Ac   15.7Bcd   22.0Ad   21.0Ad
  CFO           45.3Aa    41.0Ba   29.7Aab   26.7Ba   34.0Aab   37.7Ba   37.3Aa   35.3Ba    32.7Ab   31.7Ab

GrB- Kit used for antibiogram to analyze six anti-Gram-positive B drugs; Means followed by the same small letter in the column (drug) and capital letter in the line (extract treatment), do not differ among themselves. Tukey test, 5% probability.

###### 

Comparison of inhibition (measured in mm) of staphylococcal strains, treated by *Rauvolfia grandiflora* extract, and submitted to antibiogram towards six drugs by agar diffusion method using Gram-positive A kit.

  **Drugs**       **PEN**   **CFL**   **CLI**   **AMO**   **TET**   **OXA**                                                  
  --------------- --------- --------- --------- --------- --------- --------- -------- -------- --------- --------- -------- --------
  ATCC12228       24.0Ab    15.0Bc    40.0Aa    32.3Bb    40.0Aa    33.0Ba    28.3Ac   15.0Bc   19.3Ac    11.3Bc    36.3Aa   26.3Ba
  LSA88           23.7Ab    15.7Bc    32.3Ac    32.0Ab    27.0Ac    20.7Bd    24.3Ad   14.7Bc   18.0Acd   12.3Bbc   23.7Ac   18.3Bc
  ATCC25923       36.3Aa    21.3Bb    33.0Ac    26.3Bd    28.3Ac    19.7Bd    31.3Ab   22.3Bb   29.7Aa    25.7Ba    25.0Ac   21.7Bb
  Wood46          16.7Ac    14.7Bc    34.0Ac    29.7Bc    31.7Ab    27.3Bb    17.0Ae   14.7Bc   16.3Ad    13.7Bb    21.0Bd   25.3Aa
  Smith Diffuse   24.3Ab    23.3Aa    38.0Ab    37.0Aa    25.3Acd   25.3Ac    36.7Aa   34.3Ba   26.3Ab    25.7Aa    28.0Ab   26.0Ba

GrA- Kit used for antibiogram to analyze six anti-Gram-positive A drugs; Means followed by the same small letter in the column (strains) and capital letter in the line (extract treatment), do not differ among themselves. Tukey test, 5% probability.

###### 

Comparison of inhibition (measured in mm), among staphylococcal strains, treated by *Rauvolfia grandiflora* extract, and submitted to antibiogram towards six drugs by agar diffusion method using kit Gram-positive B.

  **Drugs**       **VAN**   **AMP**   **ERI**   **SUT**   **GEN**   **CFO**                                                    
  --------------- --------- --------- --------- --------- --------- --------- -------- --------- --------- --------- --------- --------
  ATCC12228       27.7Aa    21.3Ba    23.7Ac    13.7Bd    31.3Aa    23.7Ba    34.3Aa   22.7Bab   33.0Aa    24.0Ba    45.3Aa    41.0Ba
  LSA88           20.0Abc   14.7Bb    31.7Ab    23.7Bc    21.7Ac    13.3Bd    28.3Ab   17.7Bc    23.3Abc   17.0Bcd   29.7Ad    26.7Bd
  ATCC25923       20.7Ab    14.7Bb    37.0Ba    40.0Aa    25.7Ab    20.3Bb    32.0Aa   20.7Bbc   25.0Ab    18.7Bc    34.0Bc    37.7Ab
  Wood46          18.7Ac    14.7Bb    15.7Ad    14.3Ad    22.0Ac    17.7Bc    28.3Ab   23.0Bab   21.3Ac    15.7Bd    37.3Ab    35.3Bb
  Smith Diffuse   16.7Ad    16.0Ab    39.3Aa    35.7Ab    17.7Ad    16.7Ac    25.7Ab   24.0Ba    22.0Ac    21.0Ab    32.7Acd   31.7Ac

GrB- Kit used for antibiogram to analyze six drugs anti-Gram-positive B; Media followed by the same small letter in the column (strains) and capital letter in the line (extract treatment), do not differ among themselves. Tukey test, 5% probability.

DISCUSSION
==========

*Staphylococcus aureus* and *S. epidermidis* may represent a threat to human health and animals by surpassing host immune response with an arsenal of virulence factors, most of them based on genetic regulation, i.e. quorum sensing (QS) (3,38). Many other pathogenic bacteria use the same regulation system to secrete their virulence factors, however, polyphenols such as flavonoids from plants, can affect biofilm formation by interfering with QS in *B. cepacia* (13). Recently, epigallocatechin gallate (EGCG) from green tea, was tested for its ability to inhibit QS in *Chromobacterium violaceum*, and even following an increase in bacteria growth due to the addition of EGCG, the production of QS-dependent violacein by the organism was lower (28). Other workers have observed that hamamelitannin, a natural product found in the bark of *Hamamelis virginiana*, had no effect on drug resistance and growth *in vitro* but inhibited the quorum-sensing regulator, RNAIII, of staphylococcal strains by interfering in the competition with RAP (19). Different products, including RNAIII inhibiting peptide (RIP) and anti-TRAP IgY polyclonal antibodies were able to inhibit the growth of *S. aureus* strains (35) as observed in the present work. Inhibition of enterotoxin production by *S. aureus,* at the QS level, as suggested herein, may be due to interference with surface receptors for RAP activation and with subsequent transcription of virulence genes, including SE genes as proposed previously (4). Here, enterotoxin production was precluded in 20% by treatment of LSA 88 (bovine strain) with RGE. The method used in the present study may represent real inhibitory activity on staphylococcal enterotoxin secretion, if one compares this to SE inhibition using an agglutination test (22), which may cause misinterpretation of the results. Also, enterotoxin A inhibition was assessed using a membrane over agar method and measured by immunodifusion assay (6), which is less sensitive than ELISA SEs screening used in the present work. Alkaloid-containing extracts from different plants also show antimicrobial activity, including activity against *S. aureus* (29,9). Although we have not totally identified the constituents of RGE, alkaloids are known to be produced by this plant (7,8). Apocynaceae are known to be alkaloid-producing plants, but the alkaloids vary in their chemical structures (7,8,29). The lack of activity of the purified compound, isoreserpiline, on the staphylococci tested may be explained by the interference of others compounds present in RGE (10) or did not present activity alone. The results of the present study, using low concentrations of RGE, showed significant growth inhibition on *S. aureus* strains. In order to investigate any variation among staphylococci from different origins, the antibiogram analysis showed that most of the RGE-treated strains were affected by exposure to drugs. However, in the case of Wood46 and ATCC 25923, where inhibition zones of (OXA) and (AMP), both beta-lactamic drugs, presented inverted results for treatments compared with all other strains. Although nearly all *S. aureus* strains are resistant to PEN (12), in the present study some resistant strains after RGE treatment became sensitive to the drug, demonstrating inhibition zones between 28 and 29 mm, for resistant and sensitive β-lactamase positive *Staphylococcus*, respectively (Adapted from CLSI, M100-S17, Jan 2007). The ATCC 12228 *S. epidermidis* strain, a MSSE (Methicillin Susceptible *Staphylococcus epidermidis*), remained susceptible to all drugs but with a larger halo after RGE treatment. Results suggest that differences in antibiotic zone inhibition of treated staphylococci growth could result from the increased sensitivity of *S. aureus*. This may occur in a QS-dependent manner by interfering in *sae*, a locus related to resistance and susceptibility towards drugs in the bacteria (23,39). Taken together the results reported in the present investigation may contribute to the understanding of plant extract activities in the strains tested, although further studies are needed.
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